초록 ▼

Improved methods for forming fine particles of a material have been developed, wherein the method steps include dissolving the material in a solvent to form a dilute solution, immobilizing the dilution solution, and then removing the solvent to yield particles of the material. Methods of immobilizin

Improved methods for forming fine particles of a material have been developed, wherein the method steps include dissolving the material in a solvent to form a dilute solution, immobilizing the dilution solution, and then removing the solvent to yield particles of the material. Methods of immobilizing the dilute solution include freezing, gelation, and chelation. In a preferred embodiment, the immobilized solvent is removed by lyophilization, i.e. reducing the ambient pressure while avoiding application of sufficient heat to power a phase transition. Essentially any material and solvent for the material can be used in the methods described herein. Proteins and peptides in an aqueous solvent are the preferred systems.

대표청구항 ▼

We claim: 1. A method for making fine particles of a drug material comprising: (a) dissolving a drug material in a solvent to form a solution, (b) immobilizing the solution by freezing in a liquid nonsolvent, in a dry gas, in a vacuum, or in a reactor with controlled counter current gas stream; and

We claim: 1. A method for making fine particles of a drug material comprising: (a) dissolving a drug material in a solvent to form a solution, (b) immobilizing the solution by freezing in a liquid nonsolvent, in a dry gas, in a vacuum, or in a reactor with controlled counter current gas stream; and (c) removing the solvent from the solution by reducing the ambient pressure to a pressure sufficiently low to induce a phase transition in the solvent, thereby yielding particles comprising the drug material having a diameter between 0.5 μm and 10 microns. 2. The method of claim 1, wherein the drug material comprises a therapeutic or a diagnostic agent. 3. The method of claim 2, wherein the agent is a therapeutic agent selected from the group consisting of vasoactive agents, neuroactive agents, hormones, anticoagulants, immunomodulating agents, cytotoxic agents, antibiotics, antivirals, antisense nucleic acid sequences and fragments, antigens, and antibodies. 4. The method of claim 2, wherein the agent is a therapeutic agent selected from the group consisting of insulin, calcitonin, heparin, felbamate, and hormones. 5. The method of claim 4, wherein the therapeutic agent is insulin.